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Abstract
Objective: To enable use of clinical magnetic resonance images (MRIs) to
quantify abnormalities in normal appearing (NA) white matter (WM) and gray
matter (GM) in multiple sclerosis (MS) and to determine associations with
MS-related disability. Identification of these abnormalities heretofore has
required specialized scans not routinely available in clinical practice. Methods:
We developed an analytic technique which normalizes image intensities based
on an intensity atlas for quantification of WM and GM abnormalities in stan-
dardized MRIs obtained with clinical sequences. Gaussian mixture modeling is
applied to summarize image intensity distributions from T1-weighted and 3D-
FLAIR (T2-weighted) images from 5010 participants enrolled in a multinational
database of MS patients which collected imaging, neuroperformance and dis-
ability measures. Results: Intensity distribution metrics distinguished MS
patients from control participants based on normalized non-lesional signal dif-
ferences. This analysis revealed non-lesional differences between relapsing MS
versus progressive MS subtypes. Further, the correlation between our non-
lesional measures and disability was approximately three times greater than that
between total lesion volume and disability, measured using the patient derived
disease steps. Multivariate modeling revealed that measures of extra-lesional tis-
sue integrity and atrophy contribute uniquely, and approximately equally, to
the prediction of MS-related disability. Interpretation: These results support
the notion that non-lesional abnormalities correlate more strongly with MS-
related disability than lesion burden and provide new insight into the basis of
abnormalities in NA WM. Non-lesional abnormalities distinguish relapsing
from progressive MS but do not distinguish between progressive subtypes sug-
gesting a common progressive pathophysiology. Image intensity parameters and
existing biomarkers each independently correlate with MS-related disability.
Introduction
Multiple sclerosis (MS) is an inflammatory demyelinating
disease1 associated with neurodegeneration.2 MS-related dis-
ability is prevalent and can be substantial.3 The diagnostic
hallmark of MS is focal demyelinating lesions4 that appear as
white matter (WM) hyperintensities on T2-weighted (or
FLAIR) magnetic resonance images (MRIs).5–7 WM lesions
(WMLs) have prognostic value in individual patients.8 How-
ever, lesion burden correlates poorly with clinical disability.9
Non-lesional abnormalities are also of critical importance in
MS, yet are difficult to discern on routine MRIs.10
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MS leads to histopathological abnormalities and micro-
glial activation in WM that are not evident on routine
clinical imaging.11 These abnormalities partially predict
clinical disability.12 Gray matter (GM) pathology in both
cortical and subcortical structures often begins early in
MS13,14 and also partially correlates with disability.15
However, neither normal-appearing WM (NAWM) nor
GM pathology is readily detectable on routine clinical
imaging. Atrophy, including thalamic atrophy, strongly
predicts future disability.16 However, atrophy is a down-
stream manifestation of neurodegeneration that reflects
the sum of multiple pathologic processes. Specialized
techniques such as magnetization transfer imaging,17 dif-
fusion tractography,18 and quantitative relaxometry12 are
useful in the study of MS, but these techniques require
lengthy MRI acquisitions and specialized analyses. Conse-
quently, assessing the contribution of non-lesional pathol-
ogy to disability has previously been possible only in
research applications.
Thus, development of non-lesional imaging biomarkers
is of critical importance for assessing disease severity and
improving our understanding of the pathological basis of
disability. We developed a novel approach based on mul-
timodal voxel intensity normalization that can be applied
to standard clinical MRI datasets. This approach enables
measurement of abnormalities in non-lesional tissue that
are theoretically informationally equivalent to quantitative
relaxometry.19 We evaluated this technique in a large,
previously collected dataset of T1-weighted and T2-
weighted FLAIR images with regard to differentiating
individuals with MS from non-MS controls, distinguish-
ing between relapsing versus progressive MS subtypes,
and determining correlations with disability measures. We
hypothesized that T1-weighted and T2-weighted images,
following appropriate transform, would contain quantita-
tive measures of tissue integrity allowing for the identifi-
cation of abnormal non-lesional tissue. We tested this
hypothesis in a large observational dataset and assessed
the extent to which the information provided by our
novel analysis methodology is complimentary to conven-
tional biomarkers of MS pathology (i.e., WML burden
and atrophy).
Methods
Standard protocol and patient enrollment
Data were obtained from the MS PATHS network, com-
prising 10 sites in the United States and Europe. The MS
PATHS database contains clinical and imaging data col-
lected from a large, heterogenous MS population as part
of routine patient care. MS PATHS participants agree to
share pseudoanonymized data with the research sponsor
and the network investigators under the auspices of indi-
vidual Institutional Review Boards after providing written
informed consent. The MS PATHS database includes clin-
ical performance measures and 3D T1-weighted and 3D
FLAIR images (both 1-mm isotropic voxels) acquired on
3T Siemens scanners using a standardized imaging proto-
col. After local approval by the Institutional Review Board
at Washington University in St. Louis, data used in the
present analyses were drawn from Data Cut 6 (Down-
loaded 12/5/2018).
MS PATHS inclusion and exclusion criteria
Inclusion criteria for all MS PATHS participants included
clinically confirmed MS and ability to provide informed
consent. Additional criteria applied in the present analysis
are detailed below.
Clinical characterization in MS PATHS
Clinical measurements closest to the imaging session were
used. Many (1206) were performed the same day. In all
cases, <180 days separated sessions (mean 43 days, st. dev
50 days).
MS subtype
Patients characterized themselves as having one of the fol-
lowing types of MS: relapsing–remitting (RR), secondary
progressive (SP), primary progressive (PP), or progressive
relapsing (PR). The nomenclature regarding subtypes is
based on the original MS PATHS study design. All four
subtypes were initially analyzed separately, but statistical
analysis revealed that progressive subtypes were indistin-
guishable. Accordingly, subsequent analyses focused on
relapsing remitting versus progressive subtypes.
Patient determined disease steps
The patient determined disease steps (PDDS) is a self-re-
ported disability score with a strong correlation
(r = 0.78) to the Expanded Disability Status Scale.20
Patients rate their disability from 0 to 8, with 0 corre-
sponding to normal, (1) – mild disability, (2) – moderate
disability, (3) – gait disability, (4) – early use of a cane,
(5) – late use of a cane, (6) – bilateral support, (7) –
wheelchair or scooter dependent, and (8) – bedridden.
Objective performance testing
Performance tests were administered during clinical visits
on an iPad using the Multiple Sclerosis Performance Test
(MSPT).21 Measures were designed to simulate
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components of the multiple sclerosis functional composite
and include the processing speed test, a digital version of
the symbol digit modalities test22; the manual dexterity
test, simulating the 9-hole peg test23; and the walking
speed test, a timed 25-foot walk.24 Results from the test-
ing session closest to the MRI date were used in the pre-
sent analysis.
Quality of life evaluation
Patients ranked their subjective symptoms using the com-
puter adapted version of the Neuro-QoL.25 This instru-
ment assesses 12 domains of health-related quality of life
such as cognitive function and upper extremity use.
Results from the questionnaire closest to the scanning ses-
sion were used.
Healthy controls data collection
Healthy control data were collected at MS PATHS institu-
tions as part of an ongoing concurrent substudy. Subjects
aged 21–60 were recruited to be age, gender, and race
matched to the clinical MS PATHS population. Exclusion
criteria included comorbid neurological conditions (e.g.,
stroke, epilepsy, and Alzheimer’s disease), migraine
requiring medication, autoimmune disease, pregnancy, or
history of human immunodeficiency virus. Healthy con-
trol subjects underwent the same data collection proce-
dures (MSPT and MRI) as the MS patients.
Image processing and analysis
Basic image processing steps are described here; more
detail is available in the Supplemental Material. T1 MP-
RAGE and 3D FLAIR (1-mm3 voxels) underwent affine
alignment, brain extraction, and bias field correction.26
The fundamental principle underlying the present anal-
yses is standardization of bivariate intensity (T1w ×
FLAIR) histogram shape to match normative data. This
is a statistical approach to analysis of image intensity dis-
tributions. Differences in alignment owing to atrophy do
not affect this analysis. Normative data from 101 age-
and sex-matched controls imaged using identical proce-
dures were generated. Bivariate histograms were created
representing T1w/FLAIR voxel intensities on the horizon-
tal/vertical axes, respectively. Histogram peaks occurred at
specific loci in intensity space corresponding to distinct
tissue classes (GM, WM, CSF; Fig. 1). Individual partici-
pant histograms exhibited grossly similar shapes in
healthy controls and MS patients but subtly varied in
scale and skew across individuals (dashed lines in Fig. 1).
Intensity normalization of all participants (n = 5038)
was achieved by affine registration of individual bivariate
histograms to the reference histogram. This normalization
facilitates tissue classification and comparison. Figure 1
illustrates bivariate histograms in two example partici-
pants (1 control, 1 MS patient) before and after intensity
normalization. Histogram alignment error in each indi-
vidual was compared to a fixed criterion determined by
visual inspection of a representative sample (Figure S1).
Individuals with histogram alignment error above this
threshold (n = 28, 0.6%) were excluded. Histogram nor-
malization parameters obtained in each participant were
applied voxelwise to the T1w and FLAIR data, thereby
generating images whose bivariate histograms closely
approximated the normative reference.
Intensity normalization generated T1w and FLAIR
images in which tissue classes (CSF, WM, GM, lesion)
were represented as partially overlapping distributions
about centroids in a bivariate intensity space. Tissue seg-
mentation was achieved by implementing a procedure
similar to k-means clustering (described in the Supple-
mental Material) to compute voxelwise tissue class assign-
ments (Figure S2). Each voxel was classified as either GM,
WM, CSF, or WML. A conservative methodology was
adopted to identify unconfounded NA voxels, with
ambiguous or borderline voxels classified as lesion for this
analysis. A separate procedure was used to quantify GM
and WM volumes (see Brain atrophy measures below;
“MSPie” and Figure S2 and S3).
In principle, statistical measures could be extracted
directly from the bivariate histograms. However, MS
pathology is commonly described in terms of T1w and
FLAIR images. Therefore, to preserve the interpretability of
the present findings, we adopted a univariate approach
whereby T1 and FLAIR intensity histograms were modeled
separately. The normalized data were split into two univari-
ate histograms representing normalized T1w and FLAIR
image intensity distributions. These univariate, normalized
histograms were subsequently subjected to comparisons of
interest, for example, MS patients versus controls. Group
comparisons were computed by analysis of normalized,
univariate T1w and FLAIR intensity distributions within
tissue classes determined by Gaussian mixture modeling
(GMM). GMMs applied to T1w and FLAIR intensity distri-
butions provide a signal intensity mean (µ) and standard
deviation (σ) for each tissue class, CSF, GM, WM, and
lesion (Fig. 2A and B). These parameters (µ, σ) from GM
and WM derived from the T1w and FLAIR data were ana-
lyzed further. GMM fitting was carried out twice, once with
lesions included and again with lesions excluded.
Brain atrophy measures
MS PATHS Image Evaluation (MSPie) automatically
segments GM and WM structures and delivers estimates
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of brain parenchymal fraction (BPF), WM fraction
(WMF), GM fraction (GMF), and thalamic volume.27
These metrics, included in the MS PATHS repository,
were used to estimate atrophy. Of note, lesion masks
derived from MSPie and the present lesion score
approach are strongly similar (Supplemental Results,
Figures S2 and S3).
Statistical procedures
Evaluating differences in mean GMM parameters
between Controls and MS patients
The first investigated question was whether GMM param-
eters differ between MS patients and controls; the second
question was whether GMM parameters differ among MS
Figure 1. Demonstration of intensity alignment in control and MS patients. (A) Univariate histogram for a randomly selected control participant
demonstrates T1w intensity in blue, with highest voxel counts for intensity at approximately 200 (for CSF), 600 (for gray matter), and 1000 (for
white matter). Flair intensity in red indicates highest voxel numbers were at approximately 200 (for CSF), 700 (for white matter), and 1100 (for
gray matter). (B) The same control, bivariate, voxel-wise intensity histogram (higher voxel counts are bright) demonstrates a clustering of voxels at
T1w intensity of approximately 600 and FLAIR intensity of approximately 1100 (gray matter, left arrowhead), and another clustering of voxels at
FLAIR intensity of approximately 700 and T1w intensity of approximately 1000 (white matter, right arrowhead). (C and D) Histograms from a
randomly selected RRMS patient demonstrate abnormalities in location and distribution of peaks. Alterations in location and distribution of T1w
and FLAIR in the bivariate plot (in D) are not just due to the disease but also due to lack of normalized signal intensities owing to uninteresting
scan parameters. In (A and C), the dashed lines indicate the nonalignment of the peak loci in the T1w distribution (blue line). Based upon the
normal reference created from 101 healthy controls (E and F), intensity alignment was affine transformed for the control participant (G and H),
and the MS patient (I and J). The MS patient marginal histogram now demonstrates better normalization of T1w intensity (blue line) and
broadening of the FLAIR peak (red line) which corresponds to T2-weighted abnormalities in MS.
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subtypes. ANOVA models were fit with group (control,
RRMS, SPMS, PPMS, PRMS) as factor. Each of 8 GMM
parameters was fit separately. Thus, the significance level
was set as P < 0.05/8 = 0.00625. In cases of significant
ANOVA models, post hoc pairwise contrasts were
extracted to determine between which groups there were
significant differences.
Evaluating the relationship between biomarkers
and disability
We next sought to quantify the relationships between
biomarkers (e.g., GMM parameters, lesion volume, and
atrophy) and disability as measured by the PDDS.
Biomarkers were Z scored, thereby facilitating direct
comparison of regression β values. Each biomarker was
separately fit in a linear regression model with intercept
and PDDS as modeled factors. The β (slope) values
were of key interest as they directly reflect the strength
of the statistical relationship between biomarkers and
PDDS.
Identification of unique contributors to disability
The preceding analyses established a relationship between
PDDS and biomarkers of interest. A LASSO regression
model was fit to isolate variables uniquely contributing to
PDDS. LASSO regression eliminates variables contributing
redundant information from the model.28 To verify the
validity of the fit, a hold-out analysis was performed
Figure 2. Histogram parameters differentiate MS patients from controls. The top panels (A, B) display simulated data to demonstrate the
application of Gaussian mixture models (GMMs) to univariate histograms. Solid blue and red lines correspond to the hypothetically observed T1w
and FLAIR intensity histograms, respectively. GMM attempt to model these observed distributions as a sum of Gaussians, these Gaussians are
indicated by dashed lines. Each Gaussian is described by a mean (µ) and standard deviation (σ). These parameters are calculated for each
individual participant in WM and GM on the T1w and FLAIR image. The Gaussian corresponding to the CSF is not analyzed. The mean (standard
error) of each parameter across participants is shown in the bottom panels (C–J). Dark gray bars correspond to estimates calculated across the
entire brain mask; light gray bars correspond to estimates calculated across the brain mask with discrete WM lesions excluded. The principle
impact of lesion exclusion on GMM parameters was to reduce within-tissue class variability (σ). As a rule, MS (all subtypes) are associated with
increase σ in all measures indicating increased signal variability (wider histograms). For µ parameters, the direction varies. T1w WM and FLAIR WM
and GM appeared darker in MS patients and T1w GM appeared brighter in MS patients.
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wherein the model trained on 90% of available data was
applied to the previously unseen 10%.
Data availability statement
MS PATHS data are currently accessible to Biogen or par-
ticipating healthcare institutions in the MS PATHS pro-




Complete datasets were acquired in 5038 participants (101
healthy controls and 4937 MS patients). Of these, 5010,
including all 101 healthy controls, passed quality control
procedures based on alignment of the bivariate intensity his-
togram. MS patients comprised 68% RRMS, 18% SPMS,
6.5% PPMS, and 8% PRMS groups. Patients with RR sub-
type were more likely to be younger, female, and less dis-
abled compared to progressive subtypes (Table 1). Rates of
disease modifying therapy were similar across subtypes.
Gaussian mixture models measure
differences between MS patients and
controls
Figure 2C–J shows μ and σ corresponding to GM and
WM, in normalized T1w and FLAIR data, in healthy con-
trols, RRMS, SPMS, PPMS, and PRMS. ANOVA found
significant MS versus control differences in all but four
out of 16 combinations of image type × measure, with or
without lesions included (dark or light bars in Fig. 2;
Table S1). In particular, T1w mean WM intensity (μ) was
significantly lower in all MS subtypes (Fig. 2C) compared
to controls, indicating diffuse, WM changes in MS. Addi-
tionally, T1w WM σ was larger (wider distribution) in all
MS subtypes compared to controls (Fig. 2G), indicating
increased heterogeneity of T1w WM signal. Similarly,
FLAIR WM σ was wider in all MS subtypes compared to
controls (Fig. 2I). These outcomes were the same whether
or not lesions were included in the WM measure, indicat-
ing that NAWM is abnormally heterogenous in MS. In
the case of controls, differences owing to the inclusion or
exclusion of lesions are due to the presences of nonspeci-
fic WM hyperintensities classified as lesions likely owing
to small vessel disease or a similar process. The FLAIR
GM μ parameter performed best for discriminating con-
trol versus MS (Fig. 2F).
Figure 3 shows results obtained by post-hoc extraction
of comparisons from the ANOVA model, with lesions
excluded; μ and σ comparisons are listed above and below
the diagonal, respectively. The most significant differences
were between healthy controls and all MS subtypes (first
row or column of Fig. 3); the next most significant were
between RRMS and progressive MS subtypes (second row
or column of Fig. 3). Almost no significant differences were
found between the three progressive MS subtypes (shaded
area of each matrix). Thus, GMM analysis of normalized
intensity distributions distinguished patients with MS from
healthy controls and RR MS from progressive MS but did
not distinguish among progressive MS subtypes.
Differences in mean values are difficult to generalize to
the individual subject. We investigated the sensitivity and
specificity of the GMM parameters for determining two
comparisons: (1) control versus MS and (2) RRMS versus
progressive subtypes. Comparisons within progressive sub-
types were excluded on the basis of no mean differences
being found in the above analysis (Fig. 3). For each GMM
parameter and comparison, we calculate the ROC AUC
parameter, sensitivity, and specificity (Table 2). Overall, the
GMM parameters with the most significant differences in
mean value also had the most discriminative value as mea-
sured by the ROC. As regards discriminating controls versus
MS patients, FLAIR WM σ had the largest AUC (0.84). The
AUC of FLAIR WM µ was only 0.55 indicating that this
parameter was minimally discriminative of MS versus con-
trols. The biological interpretation of GMMparameters with
near-chance AUC is uncertain.
Table 1. Participant demographics.
Controls RRMS SPMS PPMS PRMS
N 101 3340 877 321 399
N excluded 0 17 8 2 1
Gender, %F 75% 75% 73% 64% 64%
Age in years (SD) 41.1 (11.8) 45.2 (11.9) 49.8 (11.1) 50.3 (12.5) 47.0 (12.4)
PDDS (SD) N/A 1.13 (1.53) 3.54 (1.96) 3.36 (2.29) 2.97 (2.27)
Age at diagnosis (SD) N/A 34.0 (10.4) 34.8 (11.0) 39.1 (12.3) 33.1 (11.3)
On disease modifying therapy (%) N/A 76% 69% 77% 67%
Note. Demographic information for MS PATHS participants and healthy controls. Mean (standard deviation) of selected demographic variables by
group and MS subtype. PDDS, patient determined disease steps.
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Relations between lesion-burden and
atrophy biomarkers and disability
Figure 4 relates existing lesion-based biomarkers and
brain volume-based biomarkers to PDDS evaluated over
all MS subtypes. The Z score (across the entire cohort) of
each biomarker was entered into regression analysis with
PDDS as the independent variable. The obtained regres-
sion coefficients (β) quantitate magnitude of the imaging
biomarker relation to disability and allow comparison
between alternative biomarkers. Among the six evaluated
imaging biomarkers, lesion volume (Fig. 4A) exhibited
the weakest relation to PDDS. BPF (Fig. 4C), followed by
GMF (Fig. 4E), thalamic volume (Fig. 4D), and WMF
(Fig. 4F), all out-performed lesion volume.
Relations between Gaussian mixture model
measures and disability
Figure 5 relates GMM measures in GM and WM to PDDS
in all MS subtypes (with discrete lesions excluded),
displayed as in Figure 4. Several GMM measures exhibited
close associations with PDDS. FLAIR GM μ (Fig. 5D) and
FLAIR WM σ (Fig. 5G) yielded regression values
(β = −0.13 and 0.12, respectively) that were threefold to
fourfold greater than the regression value for lesion volume
(Fig. 4A) and approximately equivalent to BPF (Fig. 4C).
Results describing the relationship between GMMmeasures
and PDDS separated by MS subtype are shown in Table S2
and discussed in Supplemental Results. The relationships
between GMM measures and PDDS were predominantly
constant across MS subtypes, but when differences emerged,
which were small, the relationship was strongest in RRMS.
The PDDS corresponds closely to the EDSS but remains a
subjective measure. Accordingly, to enhance the reliability
and interpretability of the PDDS results, we evaluated these
imaging biomarkers in relation to the neuroperformance
tests (NPT) within the MSPT and Neuro-QoL. Concordant
results were obtained with the NPT and Neuro-QoL. The
NPT and Neuro-QoL have three and 12 measures, respec-
tively. Each was reduced to a single composite score using
principal component (PC) analysis (individual measures are
Figure 3. Parametric differences separate MS from controls and relapsing MS from progressive MS. Matrices show the results of post hoc
contrasts extracted from the models shown in Table 3. Pairwise comparisons were made between each of the five groups (controls, RRMS, SPMS,
PPMS, PRMS) for each parameter. Contrasts relating to the µ parameter are shown above the diagonal and contrasts relating to the σ parameter
are shown below the diagonal. The logarithmic magnitude of the P value for the corresponding contrast is represented by number of “*” with
+P < 0.05; *P < 10−2; **P < 10−3; ***P < 10−4; ****P < 10−5. Empty boxes indicate nonsignificant contrasts. The most significant differences
were between controls and all MS subtypes (first row or column) and between RRMS and progressive MS subtypes (second row or column),
whereas differences among the three progressive subtypes were unapparent.
Table 2. GMM parameter ROC AUC.
T1 WM µ T1 GM µ T1 WM σ T1 GM σ FL WM µ FL GM µ FL WM σ FL GM σ
Control versus MS
AUC 0.77 0.72 0.66 0.65 0.55 0.82 0.84 0.54
Sensitivity 0,45 0.56 0.68 0.40 0.90 0.76 0.77 0.28
Specificity 0.83 0.77 0.60 0.82 0.13 0.77 0.72 0.82
RRMS versus progressive subtypes
AUC 0.58 0.55 0.61 0.58 0.53 0.63 0.69 0.51
Sensitivity 0.65 0.31 0.63 0.52 0.66 0.72 0.55 0.74
Specificity 0.49 0.77 0.52 0.62 0.42 0.49 0.66 0.28
Note. ROC AUC, sensitivity, and specificity for the discrimination of controls versus MS patients and RRMS versus progressive subtypes based on the eight
GMM parameters. GMM, Gaussian mixture modeling; MS, multiple sclerosis.
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listed in Table S3). The first PC explained 82% and 60% of
the variance of NPT and Neuro-QoL, respectively. As with
PDDS, FLAIR GM μ and FLAIR WM σ exhibited the stron-
gest relationships with NPT and Neuro-QoL (Table 3).
Moreover, the t scores for FLAIR GM μ and FLAIR WM σ
associations with NPT and Neuro-QoL were approximately
five times larger than the t score relating WML volume and
NPT and Neuro-QoL.WML-based measures showed no sig-
nificant relation to NPT or Neuro-QoL.
Accounting for both brain volume and
Gaussian mixture model parameters
improves correlation with disability
A subset of GMM parameters as well as volume-based mea-
sures was strongly correlated with PDDS. Specifically, this
was true of BPF (β = −0.16), FLAIR GM μ (β = −0.13),
and FLAIR WM σ (β = +0.12). To address the question of
whether these parameters provide unique versus redundant
information, we performed LASSO regression,2928 which
assigns weights to factors contributing to an outcome mea-
sure (i.e., PDDS) under a constraint (formally, L1-penalized
regression) that eliminates weak or, critically, redundant
contributions. An important consideration of LASSO
regression is the biological interpretability of the resulting
model. Inclusion of a variable in the model indicates that,
compared to other included variables, a given variable con-
tains additional explanatory power. Exclusion of a variable
does not necessarily imply that it lacks predictive power,
only that the added predictive power is less than some tun-
ing penalty. Importantly, given two equally predictive and
highly correlated variables subject to different sampling
Figure 4. Relationship between established MS imaging biomarkers and MS disability. The relationship between imaging measures of MS
patients and the patient-determined disease steps (PDDS) score are shown graphically, along with linear regression β values (shaded areas
correspond to 1 SD around the mean predicted value). Imaging measures were Z transformed such that different metrics are on the same scale,
making β values comparable across measures. The first column (A, B) shows the relationship with two measures of WM lesion burden. WM lesion
volume is the sum of voxels identified as lesions. WM lesion intensity is WM lesion volume weighted by the lesion intensity (~uvl ¼1=nL∑v∈Luvl ,
where ul is the lesion score and L is the set of voxels within a lesion). The remaining panels (C–F) show the relationship between PDDS and brain
parenchymal fraction (BPF), thalamic volume, WM fraction (WMF), and GM fraction (GMF). Of note, in all cases the lesion based measures are
outperformed by the brain volume based measures. Asterisks indicate P values. *P < 10−2; **P < 10−3; ***P < 10−4; ****P < 10−5.
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error, LASSO will include the variable with less sampling
error. The LASSO model was computed using 90% of ran-
domly selected participants and tested in the remaining
10%. Two lesion metrics (Fig. 4A and B), 4 brain volume
metrics (Fig. 4C–F), and eight GMM metrics (Fig. 5) were
included in the model, which identified two significant pre-
dictors of PDDS: BPF (β = −0.26) and FLAIR GM μ
(β = −0.12). All other variables were eliminated. This result
indicates that brain volume and FLAIR GM μ independently
contribute to correlations with disability. Applying the opti-
mized model to the 10% held-out data revealed a significant
correlation between predicted and measured PDDS
(R2 = 0.36, P < 10−16).
Discussion
MRIs are performed routinely in MS patients. We
hypothesized that, by utilizing T1w and FLAIR intensities,
additional impactful information could be obtained from
routine clinical MRIs. We developed a technique to stan-
dardize T1w and FLAIR intensity histograms derived
from images obtained with clinically available MRI
sequences. This technique was applied to data from previ-
ously acquired datasets from over 5000 MS patients and
identifying relationships with clinical disability. GMM of
the standardized histograms yielded measures that sepa-
rated MS patients from healthy controls and distinguished
between relapsing MS versus progressive MS. The two
GMM measures most correlated with disability measures
were GM mean intensity (μ) and non-lesional WM inten-
sity variability (σ) in FLAIR images. Since WM σ was
evaluated outside of discrete lesions, this measure pertains
to NAWM. LASSO regression demonstrated that GMM
analysis of standardized intensity histograms contributed
information relating to disability that was independent of
lesion burden and atrophy measures. Specifically, LASSO
Figure 5. Abnormalities in white matter and gray matter intensity and variability in non-lesional GM and WM correlate with MS disability. The
relationship between imaging measures of MS patients and the patient-determined disease steps (PDDS) score are shown graphically, along with
linear regression β values. Imaging measures were Z transformed such that different metrics are on the same scale, making β values comparable
across measures. The panels demonstrate the relationships between PDDS and intensity and variability parameter measures of non-lesional GM
and WM. Asterisks indicate P values. *P < 10−2; **P < 10−3; ***P < 10−4; ****P < 10−5.
1104 ª 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association
Diffuse Abnormalities in MS M. R. Brier et al.
identified FLAIR GM μ which may reflect sensitivity to
cortical lesions not readily appreciable on visual inspec-
tion of the images. This novel analysis technique provides
quantitative insights into non-lesional WM pathology in
MS and its relation to disability. Moreover, this powerful
technique provides a practical method that can be used to
derive quantitative information from clinical brain
images, including those acquired previously such as MRIs
done in prior clinical trials.
T1 and T2 are intrinsic physical properties of neural
tissue29 that depend on cellular composition.30,31 Absolute
measurement of T1 and T2 can be obtained using multi-
echo MRI sequences.12 Such quantitative measures can
serve as biomarkers of disease.32 MS-related changes in
T1 and T2 are well documented in both the WM and
GM, within33 and outside34 discrete lesions. For example,
T2 is prolonged in MS NAWM.34 T1 and T2 are propor-
tionally reflected in T1w and T2w (FLAIR) images in a
manner that depends on sequence parameters (i.e., TR,
TE, presence of suppression pulses, etc.). Variations in
these parameters among clinical scans preclude direct
recovery of absolute T1 and T2 from T1w and T2w
images. The present histogram normalization technique
overcomes this barrier by representing T1w and T2w data
in a standard bivariate intensity space. Standardized
intensities are informationally equivalent to absolutely
measured T1 and T219 assuming that T1w and T2w
images encode a linear combination of T1 and T2. In
practice, this assumption is only approximate as
reconstructed image intensities depend on T1 and T2
nonlinearly.35 Nevertheless, we have demonstrated the
utility of our approach using T1w and FLAIR imaging
data. The fundamentals underlying this approach easily
accommodate additional imaging contrasts (e.g., suscepti-
bility-weighted images).
The present results using our novel analysis method are
concordant with results obtained using quantitative relax-
ometry but without the technical challenges of the latter
procedure. Our results recapitulate that WM T2 (FLAIR)
heterogeneity is increased in MS compared to controls36
and in progressive MS compared to relapsing MS.37 Thus,
results derived from the present method parallel results
obtained with quantitative T1 or T2 imaging,38 while
being accessible in clinically acquired data standardized
imaging data.
The present findings provide several insights. Intensity-
based measures derived from the GMM approach sepa-
rated RRMS from progressive disease but did not distin-
guish between progressive disease subtypes (PPMS vs.
SPMS vs. PRMS). This result is consistent with the con-
cept that all progressive subtypes have similar underlying
tissue damage, likely representing the same underling
pathologic process. Second, we compared the GMM
intensity-based method to lesion volume metrics and esti-
mates of atrophy using BPF, WMF, GMF, and thalamic
volume, head to head. The present intensity-based mea-
sures and volume-based measures were independently
correlated with MS-related disability. Hence, considera-
tion of both could enhance tracking of disease dynamics.
Third, the variability in FLAIR signal intensity in NAWM
was strongly correlated with disability. T2 (FLAIR) corre-
lates with myelin content, axon count and other histologi-
cal features in post-mortem MS tissue.39 T2 changes are
not homogenously distributed across NAWM.37 The most
abnormal areas are prone to developing lesions in the
future.40 One possible contributor to this observation
could be small, subresolution discrete lesions which mani-
fest as signal variability in NAWM. Speculatively, the pre-
sent normalized T2 (FLAIR) signal properties may reflect
this same histopathological variability evident in quantita-
tive relaxometry and ex vivo imaging. FLAIR signal vari-
ability was approximately fourfold more strongly
correlated with disability compared to FLAIR mean inten-
sity. This result motivates future study of the pathological
basis of this finding.
Focal WMLs remain the imaging hallmark of MS diag-
nosis.41 However, lesion burden is known to be a poor
predictor of disability9 especially at later stages of the dis-
ease.42 Models that incorporate lesion location are moder-
ately more predictive.43 Pathology outside of discrete
lesions is increasingly recognized as important in MS.44
Thus, it is noteworthy that the GMM parameter FLAIR
Table 3. Neuroperformance and Neuro-QoL statistical results.
NPT Neuro-QoL
t P t P
T1w WM μ +7.27 <10−13 +0.65 –
T1w GM μ −11.59 <10−16 −1.76 –
T1w WM σ −0.11 – +0.28 –
T1w GM σ −12.26 <10−16 +1.01 –
FLAIR WM μ +6.47 <10−9 +1.02 –
FLAIR GM μ +26.45 <10−16 +3.50 <10−3
FLAIR WM σ −26.16 <10−16 −4.52 <10−5
FLAIR GM σ −4.09 <10−4 +0.46 –
WM Les Vol −5.28 <10−6 −1.31 –
WM Les Intens −8.45 <10−16 −1.99 –
Note. Main effects derived by linear regression of GMM parameters
on first principal components of neuroperformance tests (NPT) in the
MSPT and Neuro-QoL scores. t values indicate the strength and direc-
tion of the relation. Only significant P values (uncorrected for multiple
comparisons) are listed. The effect size of several GMM parameters
was larger than the effect size of lesion burden metrics. Significant
effects of σ generally were negative, indicating that greater signal
variability is related to greater impairment. The direction of the effect
of μ on performance was not consistent. GMM, Gaussian mixture
modeling.
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WM σ (Table 2) exhibited an AUC of 0.84 for discrimi-
nating controls versus MS patients. From a statistical per-
spective, an AUC of 0.84 is significant. However,
nonunity is congruent with the observation that NAWM
abnormalities are variably present at least partially related
to level of disability (Fig. 5). Whereas immune-mediated
inflammation is a critical component of lesion pathol-
ogy,45 abnormalities in NAWM may be more related to
injury and repair.46 We observed a less strong relationship
between GMM parameters and disability in progressive
patients compared to relapsing patients, in agreement
with prior studies.47 This result may reflect different
pathologies in relapsing versus progressive MS, and it
may also reflect the contributions of spinal cord pathol-
ogy to disability in progressive MS,48 which was not
assessed in this study.
The present analysis method provides estimates of GM
integrity as well as WM measures. GM damage is increas-
ingly recognized as a driver of MS-related disability.49 In
parallel to WM abnormalities, GM can contain discrete
lesions, detectable only with specialized sequences, as well
as diffuse abnormalities. GM pathology may affect neuron
cell bodies, axons, dendrites, myelin, glia, and extracellu-
lar matrix.12 GM disease has been related to WML bur-
den,50 but the causal mechanism underlying this relation
remains unclear. Quantitative GM T1w signal abnormali-
ties have been associated with clinical status.38 We
demonstrated that changes in T1w and FLAIR signal
intensity within GM significantly correlate with clinical
disability. It is possible that the present technique can
quantify subtle changes in T1 and FLAIR associated with
GM lesions as well as diffuse abnormalities.
Limitations of the present study include that the analy-
ses were cross-sectional and drawn from an observational
cohort. Longitudinal, prospective analyses are planned to
clarify the short- and long-term correlates and predictive
power of abnormalities in GMM parameters. The MS
PATHS protocol does not include spinal imaging; thus,
we could not assess contributions of spinal cord pathol-
ogy to MS-related disability. In MS PATHS, clinical sub-
type is self-reported, and the PDDS is a subjective
patient-reported outcome. However, the MSPT was
included in the present work and provided objective sup-
port for the results.
These analyses used a standard MRI protocol at 3T.
Theoretically, this approach can be applied to other data-
sets obtained at lower field strengths or nonstandardized
imaging acquisition. If confirmed, it may be possible to
use this technique to analyze archival clinical trial data
and other large, pre-existing databases. This method
might be particularly promising in the reanalysis of prior
trials of progressive MS in which results were equivocal
or only benefited subgroups of patients. The present
intensity normalization technique does have some limita-
tions. First, it relies on the alignment of a measured his-
togram to a reference which can be affected by subtle
movement impacting numeric results in subtle ways. In
the present work, there were no strong correlations
between alignment error and outcomes of interest (see
Supplemental Methods). Additionally, while intensity
alignment transforms images to a standard intensity
space, the numerical values remain arbitrary precluding
direct comparison to prior quantitative relaxometry
results. Since this study uses standardized imaging proto-
cols, comprehensive evaluation of interprotocol analysis is
reserved for future work.
Conclusions
We report a novel technique for quantification of non-le-
sional abnormalities in WM and GM in MS using data
obtained with clinically available MR sequences. Using
this new approach, we demonstrate diffuse changes in
GM and WM in MS patients compared to healthy con-
trols and differences between relapsing versus progressive
disease. Importantly, these changes were more strongly
correlated with disability than conventional lesion-based
metrics and comparably correlated with volume-based
metrics, reinforcing that non-lesional abnormalities are a
critical component of MS pathophysiology. Our results
also support the notion that progressive non-lesional
pathology is similar across progressive subtypes. The pre-
sent approach enables quantification of abnormalities
using conventional MRI protocols, allowing this tech-
nique to be used in clinical populations. Future work will
investigate the power of this approach to predict disease
progression and monitor response to therapy.
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